Last reviewed · How we verify
Standard dose lamotrigine — Competitive Intelligence Brief
marketed
Anticonvulsant / Antiepileptic drug
Voltage-gated sodium channels; glutamate release inhibition
Neurology
Small molecule
Live · refreshed every 30 min
Target snapshot
Standard dose lamotrigine (Standard dose lamotrigine) — Mario Negri Institute for Pharmacological Research. Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Standard dose lamotrigine TARGET | Standard dose lamotrigine | Mario Negri Institute for Pharmacological Research | marketed | Anticonvulsant / Antiepileptic drug | Voltage-gated sodium channels; glutamate release inhibition | |
| Lamictal TM | Lamictal TM | Central Mental Clinic for Outpatients of Baku City | marketed | Anticonvulsant / Mood stabilizer | Voltage-gated sodium channels; glutamate release inhibition | |
| Brand lamotrigine | Brand lamotrigine | University of Maryland, Baltimore | marketed | Anticonvulsant / Mood stabilizer | Voltage-gated sodium channels; glutamate release inhibition | |
| Lamotrigine generic "B" | Lamotrigine generic "B" | University of Cincinnati | marketed | Anticonvulsant / Mood stabilizer | Voltage-gated sodium channels; glutamate release inhibition | |
| lamotrigine (generic Teva) | lamotrigine (generic Teva) | University of Maryland, Baltimore | marketed | Anticonvulsant / Mood stabilizer | Voltage-gated sodium channels; glutamate release inhibition | |
| Generic lamotrigine | Generic lamotrigine | University of Maryland, Baltimore | marketed | Anticonvulsant / Mood stabilizer | Voltage-gated sodium channels; glutamate release inhibition | |
| lamotrigine (brand Lamictal) | lamotrigine (brand Lamictal) | University of Maryland, Baltimore | marketed | Anticonvulsant / Mood stabilizer | Voltage-gated sodium channels; glutamate release inhibition |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Anticonvulsant / Antiepileptic drug class)
- Mario Negri Institute for Pharmacological Research · 3 drugs in this class
- Eisai Inc. · 2 drugs in this class
- Affiliated Hospital of Nantong University · 1 drug in this class
- GlaxoSmithKline · 1 drug in this class
- MaineHealth · 1 drug in this class
- UCB Pharma · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Standard dose lamotrigine CI watch — RSS
- Standard dose lamotrigine CI watch — Atom
- Standard dose lamotrigine CI watch — JSON
- Standard dose lamotrigine alone — RSS
- Whole Anticonvulsant / Antiepileptic drug class — RSS
Cite this brief
Drug Landscape (2026). Standard dose lamotrigine — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-dose-lamotrigine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab